NCT05481437View on ClinicalTrials.gov

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

RecruitingOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Brentuximab Vedotin injection, 50 mg, once every 2 weeks

Trial Locations (1)

Unknown

RECRUITING

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05481437 - A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter